Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 158

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study

Open access
Hanny Al-Samkari, Raj S. Kasthuri, Joseph G. Parambil, Hasan A. Albitar, Yahya A. Almodallal, Carolina Vázquez, Marcelo M. Serra, Sophie Dupuis-Girod, Craig B. Wilsen, Justin P. McWilliams, Evan H. Fountain, James R. Gossage, Clifford R. Weiss, Muhammad A. Latif, Assaf Issachar, Meir Mei-Zahav, Mary E. Meek, Miles Conrad, Josanna Rodriguez-Lopez, David J. Kuter, Vivek N. Iyer · 2020 · Haematologica

Abstract

Hereditary hemorrhagic telangiectasia (HHT, Osler-Weber-Rendu disease) is a rare multisystem vascular disorder causing chronic gastrointestinal bleeding, epistaxis, and severe anemia. Bevacizumab, an anti-vascular endothelial growth factor antibody, may be effective to treat bleeding in HHT. This international, multicenter, retrospective study evaluated the use of systemic bevacizumab to treat HHT-associated bleeding and anemia at 12 HHT treatment centers. Hemoglobin, epistaxis severity score, red cell units transfused, and intravenous iron infusions before and after treatment were evaluated using paired means testing and mixed-effects linear models. 238 HHT patients received bevacizumab for a median of 12 (range, 1-96) months. Compared with pretreatment, bevacizumab increased mean hemoglobin by 3.2 g/dL (95% CI, 2.9-3.5 g/dL) [mean hemoglobin 8.6 (8.5, 8.8) g/dL versus 11.8 (11.5, 12.1) g/dL, p

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3324/haematol.2020.261859

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 158

Metadata

Authors
Al-Samkari, H., Kasthuri, R. S., Parambil, J. G., Albitar, H. A., Almodallal, Y. A., Vázquez, C., Serra, M. M., Dupuis-Girod, S., Wilsen, C. B., McWilliams, J. P., Fountain, E. H., Gossage, J. R., Weiss, C. R., Latif, M. A., Issachar, A., Mei-Zahav, M., Meek, M. E., Conrad, M., Rodriguez-Lopez, J., Kuter, D. J., & Iyer, V. N.
Venue
Haematologica
Published
2020-07-16
Volume
106
Issue
8
Pages
2161-2169
ISSN
  • 0390-6078 (ISSN-L)
  • 1592-8721
OpenAlex
W3043395065
Cited by
158
References
2
FWCI
7.43
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study. https://app.cochat.ai/papers/10.3324/haematol.2020.261859
The paper
Al-Samkari, H., Kasthuri, R. S., Parambil, J. G., Albitar, H. A., Almodallal, Y. A., Vázquez, C., Serra, M. M., Dupuis-Girod, S., Wilsen, C. B., McWilliams, J. P., Fountain, E. H., Gossage, J. R., Weiss, C. R., Latif, M. A., Issachar, A., Mei-Zahav, M., Meek, M. E., Conrad, M., Rodriguez-Lopez, J., . . . Iyer, V. N. (2020). An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study. Haematologica. https://doi.org/10.3324/haematol.2020.261859

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.